Zacks Research Comments on Longeveron FY2028 Earnings

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Zacks Research issued their FY2028 EPS estimates for shares of Longeveron in a research report issued on Tuesday, February 17th. Zacks Research analyst B. Sorensen anticipates that the company will earn ($1.65) per share for the year. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.50.

Longeveron Price Performance

Shares of LGVN opened at $0.56 on Thursday. The firm has a market cap of $11.98 million, a PE ratio of -0.53 and a beta of 0.21. The stock’s fifty day moving average price is $0.56 and its two-hundred day moving average price is $0.71. Longeveron has a 1 year low of $0.49 and a 1 year high of $1.92.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd acquired a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.